Literature DB >> 9006937

Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.

K Kennedy1, V Gigoux, C Escrieut, B Maigret, J Martinez, L Moroder, D Fréhel, D Gully, N Vaysse, D Fourmy.   

Abstract

A region between residues 38 and 42 of the human cholecystokinin-A (CCK-A) receptor was shown to be involved in the binding of CCK but not in that of JMV 179 and JMV 180, two peptides closely related to CCK (Kennedy, K., Escrieut, C., Dufresne, M., Clerc, P., Vaysse, N., and Fourmy, D. (1995) Biochem. Biophys. Res. Commun. 213, 845-852). In the present study, we have identified the residues of both the receptor and the ligand responsible for this differential binding. Residues Trp-39 and Gln-40 of the receptor were crucial for binding of the C-terminal nonapeptide of CCK as W39F and Q40N mutants demonstrated parallel decreases in both affinity and potency to induce accumulation of inositol phosphates (12.9- and 20.9-fold). The W39F and Q40N mutant receptors bound CCK analogues modified at their C-terminal end, including JMV 179 and JMV 180, as well as the C-terminal amidated heptapeptide of CCK, with identical affinities to the wild-type receptor. In contrast, W39F and Q40N mutants bound CCK octapeptide with the same decreased affinity as the CCK nonapeptide. The modeling of the CCK-A receptor and the docking of the peptide agonists [Thr,Nle]CCK9 and CCK-8 indicated that their N terminus was connected to the receptor through a strong bond network involving Trp-39 and Gln-40 thus confirming experimental data. These first molecular data identifying the agonist binding site of the human CCK-A receptor represent an important step toward the complete delineation of the agonist binding site and the understanding of the molecular mechanisms that govern differential activation of this receptor by CCK-related peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006937     DOI: 10.1074/jbc.272.5.2920

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

3.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

4.  Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.

Authors:  Géraldine Ibarz; Catherine Oiry; Eric Carnazzi; Philippe Crespy; Chantal Escrieut; Daniel Fourmy; Jean Claude Galleyrand; Didier Gagne; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 5.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

6.  Flexibility and extracellular opening determine the interaction between ligands and insect sulfakinin receptors.

Authors:  Na Yu; Moises João Zotti; Freja Scheys; Antônio S K Braz; Pedro H C Penna; Ronald J Nachman; Guy Smagghe
Journal:  Sci Rep       Date:  2015-08-12       Impact factor: 4.379

7.  Cholecystokinin receptors in Atlantic salmon: molecular cloning, gene expression, and structural basis.

Authors:  Raja M Rathore; Anna R Angotzi; Ann-Elise O Jordal; Ivar Rønnestad
Journal:  Physiol Rep       Date:  2013-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.